文献速递糖尿病

胰岛自身免疫与HLA标志物预测症状前及临床1型糖尿病:芬兰、德国、瑞典和美国前瞻性队列联合分析

Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S.
PubMed 文献 · Diabetes Care · 2021-01-01

该研究联合芬兰、德国、瑞典和美国的前瞻性队列,纳入24,662名遗传高风险儿童,经HLA协调后分析16,709名2.5岁前入组婴幼儿。结果显示 seroconversion 时自身抗体数目可可靠预测15年1型糖尿病风险,单抗体持续者HLA-DR-DQ基因型可进一步细化进展风险。

要点

  • seroconversion时自身抗体数目预测15年糖尿病风险:1、2、3个抗体分别为45%、85%、92%。
  • 单抗体者2年后状态决定风险:转阴12%、维持单抗体30%、发展为多抗体82%。
  • HLA-DR-DQ影响稳定单抗体者的进展风险,高 vs 低风险基因型15年糖尿病发生率40% vs 12%。

核心结论

  • seroconversion时胰岛自身抗体数目可可靠预测15年1型糖尿病风险。
  • 持续单抗体儿童中,HLA-DR-DQ基因型可进一步细化进展风险。

研究设计与样本

  • 联合芬兰、德国、瑞典和美国的前瞻性队列,纳入24,662名遗传高风险儿童。
  • 经HLA协调后,分析16,709名2.5岁前入组的婴幼儿。

主要发现

  • 婴幼儿队列中1,413名(8.5%)发生至少一种自身抗体经连续两次以上访视确认(seroconversion),865名(5%)发生多抗体,655名(4%)进展为糖尿病。
  • seroconversion时1、2、3个抗体者的15年糖尿病累积发生率分别为45%(95% CI 40-52)、85%(78-90)、92%(85-97)。
  • 单抗体者seroconversion后2年状态预测糖尿病风险:转阴12%(10-25)、维持单抗体30%(20-40)、发展为多抗体82%(80-95)。
  • 稳定单抗体者中,HLA-DR-DQ高风险 vs 低风险基因型的15年糖尿病发生率分别为40%(28-50) vs 12%(5-38)。
  • 进展至糖尿病的速率与发生多抗体时的年龄呈负相关,≤2岁 vs >7.4岁发生多抗体者分别为每年20% vs 每年6%。

临床怎么用

  • 对遗传高风险儿童,seroconversion时自身抗体数目可用于分层15年1型糖尿病风险。
  • 持续单抗体儿童可结合HLA-DR-DQ基因型进一步细化进展风险。
  • 单抗体者seroconversion后2年抗体状态变化有助于动态评估糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To combine prospective cohort studies, by including HLA harmonization, and estimate risk of islet autoimmunity and progression to clinical diabetes. RESEARCH DESIGN AND METHODS: For prospective cohorts in Finland, Germany, Sweden, and the U.S., 24,662 children at increased genetic risk for development of islet autoantibodies and type 1 diabetes have been followed. Following harmonization, the outcomes were analyzed in 16,709 infants-toddlers enrolled by age 2.5 years. RESULTS: In the infant-toddler cohort, 1,413 (8.5%) developed at least one autoantibody confirmed at two or more consecutive visits (seroconversion), 865 (5%) developed multiple autoantibodies, and 655 (4%) progressed to diabetes. The 15-year cumulative incidence of diabetes varied in children with one, two, or three autoantibodies at seroconversion: 45% (95% CI 40-52), 85% (78-90), and 92% (85-97), respectively. Among those with a single autoantibody, status 2 years after seroconversion predicted diabetes risk: 12% (10-25) if reverting to autoantibody negative, 30% (20-40) if retaining a single autoantibody, and 82% (80-95) if developing multiple autoantibodies. HLA-DR-DQ affected the risk of confirmed seroconversion and progression to diabetes in children with stable single-autoantibody status. Their 15-year diabetes incidence for higher- versus lower-risk genotypes was 40% (28-50) vs. 12% (5-38). The rate of progression to diabetes was inversely related to age at development of multiple autoantibodies, ranging from 20% per year to 6% per year in children developing multipositivity in ≤2 years or >7.4 years, respectively. CONCLUSIONS: The number of islet autoantibodies at seroconversion reliably predicts 15-year type 1 diabetes risk. In children retaining a single autoantibody, HLA-DR-DQ genotypes can further refine risk of progression.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Anand V, Li Y, Liu B, et al. Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S. Diabetes Care. 2021. PMID: 34162665. doi:10.2337/dc20-1836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。